Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Co.'s product pipeline includes batoclimab and IMVT-1402, both of which are fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor. Co. is developing batoclimab, its first prodcut candidate, and IMVT-1402, its second product candidate, in autoimmune diseases for which there is evidence that pathogenic IgG antibodies drive disease manifestation. Co. is developing batoclimab for myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy and Graves' disease. We show 20 historical shares outstanding datapoints in our IMVT shares outstanding history coverage, used to compute IMVT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing IMVT market cap history over the course of time is important for investors
interested in comparing IMVT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of IMVT versus a peer is one thing; comparing
IMVT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like IMVT can fluctuate over the course of history.
With this page we aim to empower investors researching IMVT by allowing them to research the IMVT market cap history. |
Free IMVT Email Alerts:
Video: The Importance of Market Cap
